Research Topics
| Martee L HensleySummaryAffiliation: Memorial Sloan-Kettering Cancer Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapyMargrit M Juretzka
Gynecology Oncology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Gynecol Oncol 104:176-80. 2007..A secondary objective was to assess the relationship of CA125 level to PFS...
Non-mammary metastases to the breast and axilla: a study of 85 casesDeborah F Delair
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Mod Pathol 26:343-9. 2013..This finding emphasizes the need to accurately identify these tumors as metastases in order to avoid unnecessary procedures and treatments in these patients...
Impact of incorporating an algorithm that utilizes sentinel lymph node mapping during minimally invasive procedures on the detection of stage IIIC endometrial cancerM M Leitao
Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Gynecol Oncol 129:38-41. 2013..To determine whether the frequency of cases diagnosed with stage IIIC endometrial cancer is affected by the incorporation of a modified surgical lymph node assessment...
Surgical cytoreduction in patients with metastatic uterine leiomyosarcoma at the time of initial diagnosisMario M Leitao
Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Gynecol Oncol 125:409-13. 2012..To determine whether cytoreduction is associated with improved outcome in patients newly diagnosed with metastatic uterine leiomyosarcoma (LMS)...
Introduction of a computer-based surgical platform in the surgical care of patients with newly diagnosed uterine cancer: outcomes and impact on approachMario M Leitao
Division of Gynecology, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Gynecol Oncol 125:394-9. 2012..To assess the introduction of computer-based surgery (ie, robotic surgery [RBT]) in the treatment of patients with newly diagnosed uterine cancer...
Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinomaRobert A Soslow
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Mod Pathol 25:625-36. 2012..60 (95% CI, 0.32-0.84) and a negative predictive value of 1.0 (95% CI, 0.63-1.0)). These preliminary data indicate potential strong associations between morphology and genotype in high-grade serous carcinomas...
Immunohistochemical expression of estrogen and progesterone receptors and outcomes in patients with newly diagnosed uterine leiomyosarcomaMario M Leitao
Departments of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Gynecol Oncol 124:558-62. 2012..We assessed the IHC expression of ER and PR and their prognostic significance in uterine leiomyosarcoma (LMS)...
CA125 regression in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy: a gynecologic oncology group studyGinger J Gardner
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Gynecol Oncol 124:216-20. 2012..The purpose of this study is to identify the rate of CA125 regression during intraperitoneal (IP) versus intravenous (IV) chemotherapy for ovarian cancer...
Reproductive issues in the gynecologic cancer patientJeanne Carter
Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Oncology (Williston Park) 21:598-606; discussion 606-9. 2007..Education and support are clearly an essential component of cancer survivorship. Furthermore, more attention and investigation is still needed about the reproductive issues of gynecologic cancer survivors in the future...
Nomogram for survival after primary surgery for bulky stage IIIC ovarian carcinomaDennis S Chi
Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, MRI 1026, New York, NY 10021, USA
Gynecol Oncol 108:191-4. 2008..To date, only one prediction model has been reported for patients with epithelial ovarian carcinoma (EOC). The objective of this study was to develop a more accurate survival nomogram for patients with bulky stage IIIC EOC...
Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disDennis S Chi
Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA or
J Clin Oncol 25:4946-51. 2007..To compare surgeons' operative assessments of residual disease (RD) to those identified on postoperative computed tomography (CT) scans in patients with advanced ovarian carcinoma reported to have undergone optimal primary cytoreduction...
Initial experience with Dargent's operation: the radical vaginal trachelectomyY Sonoda
Department of Surgery, Gynecology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Gynecol Oncol 108:214-9. 2008..To report on our initial experience with radical vaginal trachelectomy for patients with early-stage cervical cancer...
The incidence of pelvic lymph node metastasis by FIGO staging for patients with adequately surgically staged endometrial adenocarcinoma of endometrioid histologyD S Chi
Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York 10021, USA
Int J Gynecol Cancer 18:269-73. 2008..These data are more applicable to current surgical practice than the previously described one-third myometrial invasion cutoff results...
Current and future surgical approaches in the management of endometrial carcinomaMario M Leitao
Memorial Sloan Kettering Cancer Center, Gynecology Service, Department of Surgery, 1275 York Avenue, NY 10065, USA
Future Oncol 4:389-401. 2008..Surgical cytoreduction of metastatic disease is also associated with improved outcomes...
Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trialMartee L Hensley
Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Gynecol Oncol 109:329-34. 2008..Fixed-dose rate gemcitabine plus docetaxel is active as second-line therapy for metastatic uterine leiomyosarcoma. We sought to determine the activity of this regimen as first-line treatment...
Concurrent carboplatin/paclitaxel and intravaginal radiation in surgical stage I-II serous endometrial cancerKaled M Alektiar
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Gynecol Oncol 112:142-5. 2009..To report a single institution experience in surgical stage I-II serous endometrial cancer using combined carboplatin/paclitaxel and intravaginal radiation (IVRT)...
A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumorsMartee L Hensley
Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Invest New Drugs 25:335-41. 2007..Attempts to increase the dose of BMS-247550 by decreasing the gemcitabine dose did not sufficiently ameliorate myelosuppression. Stable disease was observed in some patients with prior taxane exposure...
Twelve-year experience in the management of endometrial cancer: a change in surgical and postoperative radiation approachesRichard R Barakat
Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Gynecol Oncol 105:150-6. 2007..The purpose of this study was to analyze the results of these changes...
Psychiatric illness presenting with a sexual complaint and management by psychotropic medications: a case reportMichael Krychman
Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
J Sex Med 5:223-6. 2008..The rare disorder of reverse delusional misidentification syndrome may be encountered in schizophrenic patients and may be best managed by the combined team effort of a sexual medicine specialist and psychiatrist...
Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cellsJakob Dupont
Department of Medicine, Memorial Sloan Kettering Cancer Center and the Joan and Sanford Weill Medical College of Cornell University and Immunology Program, Sloan Kettering Institute, New York, New York 10021, USA
Cancer Res 65:5417-27. 2005....
Laparoscopic and hand-assisted laparoscopic splenectomy for recurrent and persistent ovarian cancerDennis S Chi
Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, MRI 1026, New York, NY 10021, USA
Gynecol Oncol 101:224-7. 2006..The purpose of this study was to report the outcomes of a series of patients who underwent splenectomy for persistent or recurrent ovarian cancer via laparoscopy or hand-assisted laparoscopy...
Screening and the prevention of gynecologic cancer: endometrial cancerYukio Sonoda
Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Best Pract Res Clin Obstet Gynaecol 20:363-77. 2006..Screening for these cancers is not effective and often leads to additional unnecessary tests; thus, it is not currently recommended in the general population...
Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioningMartee L Hensley
Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 275 York Avenue, New York, NY 10021, USA
Gynecol Oncol 102:270-7. 2006....
Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinomaDennis S Chi
Gynecology Service, Department of Surgery Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Cancer 106:1933-9. 2006....
Brain cancer and sexual health: a case reportMichael L Krychman
Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Palliat Support Care 2:315-8. 2004..However, the sexual concerns of these patients are often overlooked. Brain cancer patients are no exception to this oversight...
What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?D S Chi
Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Gynecol Oncol 103:559-64. 2006..The objective of this study was to analyze survival rates at very specific residual disease diameters to determine the optimal goal of primary cytoreduction for bulky stage IIIC EOC...
The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer CenterNadeem R Abu-Rustum
Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Gynecol Oncol 103:714-8. 2006..To describe the incidence of symptomatic postoperative lower-extremity lymphedema in women treated for uterine corpus cancer, and to evaluate its relationship to regional lymph node removal and postoperative therapy...
Cystoscopic temporary ureteral catheterization during radical vaginal and abdominal trachelectomyNadeem R Abu-Rustum
Gynecology Service, Department of Surgery Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Gynecol Oncol 103:729-31. 2006..To describe the role of temporary retrograde ureteral catheterization at the time of fertility-sparing radical vaginal or abdominal trachelectomy in women with early-stage cervical cancer...
A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinomaDennis S Chi
Department of Surgery, Gynecology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Gynecol Oncol 112:6-10. 2009....
Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective studyMartee L Hensley
Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
Gynecol Oncol 112:563-7. 2009..We sought to determine whether adjuvant gemcitabine-docetaxel would yield a 2-year progression-free survival of at least 50% in this leiomyosarcoma population...
Comparison of D&C and office endometrial biopsy accuracy in patients with FIGO grade 1 endometrial adenocarcinomaMario M Leitao
Department of Surgery, Division of Gynecology, Memorial Sloan Kettering Cancer Center 1275 York Avenue New York, NY 10065, USA
Gynecol Oncol 113:105-8. 2009..To compare the accuracy of D&C vs office endometrial biopsy in predicting final post-hysterectomy FIGO grade in patients diagnosed with a preoperative FIGO grade 1 endometrial adenocarcinoma...
The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomasDennis S Chi
Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Gynecol Oncol 119:38-42. 2010..To assess the morbidity and mortality associated with extensive upper abdominal surgery (EUAS) performed during primary cytoreduction for advanced ovarian carcinoma...
Postoperative intra-abdominal collections using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier at the time of laparotomy for uterine or cervical cancersMario M Leitao
Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Gynecol Oncol 119:208-11. 2010..The primary objective of the current study was to determine whether the use of HA-CMC is associated with the development of postoperative intra-abdominal collections in patients undergoing laparotomy for uterine or cervical malignancies...
A 2-year prospective study assessing the emotional, sexual, and quality of life concerns of women undergoing radical trachelectomy versus radical hysterectomy for treatment of early-stage cervical cancerJeanne Carter
Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Gynecol Oncol 119:358-65. 2010..To prospectively assess and describe the emotional, sexual, and QOL concerns of women with early-stage cervical cancer undergoing radical surgery...
Fertility considerations in the management of gynecologic malignanciesNicole Noyes
Division of Reproductive Endocrinology, New York University School of Medicine, New York, NY 10016, USA
Gynecol Oncol 120:326-33. 2011..Fertility preservation (FP) has become an integral component in the selection and execution of gynecological cancer management. In this report we address gynecologic malignancies as they relate to future fertility potential...
A cross-sectional cohort study of infertile women awaiting oocyte donation: the emotional, sexual, and quality-of-life impactJeanne Carter
Department of Psychiatry, Gynecology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Fertil Steril 95:711-6.e1. 2011..To examine the emotional, sexual, physical, and quality-of-life (QOL) impact on infertile women awaiting oocyte donation...
Fertility-sparing surgery in early-stage cervical cancer: indications and applicationsNadeem R Abu-Rustum
Department of Surgery, Gynecology Service, Memorial Sloan Kettering Cancer Center, New York
J Natl Compr Canc Netw 8:1435-8. 2010..Investigation into alternative fertility-sparing adjuvant therapy in patients with node-positive disease is needed...
Recovery issues of fertility-preserving surgery in patients with early-stage cervical cancer and a model for survivorship: the physician checklistJeanne Carter
Department of Psychiatry and Behavioral Sciences, and Surgery, Gynecology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Int J Gynecol Cancer 21:106-16. 2011....
The revised 2009 FIGO staging system for endometrial cancer: should the 1988 FIGO stages IA and IB be altered?Nadeem R Abu-Rustum
Department of Surgery, Gynecology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Int J Gynecol Cancer 21:511-6. 2011..We sought to describe the overall survival (OS) of women with stage I endometrial cancer and examine how the estimated stage-specific OS is altered in the 2009 system...
Surgical management of recurrent ovarian cancerMario M Leitao
Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Semin Oncol 36:106-11. 2009..Surgery also plays a role in the palliation of certain patients. Continued investigations, especially randomized trials, are needed to further define the optimal treatment modalities for these patients...
Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomasMartee L Hensley
Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Curr Opin Oncol 22:356-61. 2010..The activity of this regimen in advanced uterine leiomyosarcoma, other soft-tissue sarcomas, and pediatric sarcomas is discussed...
A cross-sectional study of the psychosexual impact of cancer-related infertility in women: third-party reproductive assistanceJeanne Carter
Department of Psychiatry, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
J Cancer Surviv 4:236-46. 2010....
Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigmDennis S Chi
Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Gynecol Oncol 114:26-31. 2009..To determine the impact on progression-free survival (PFS) and overall survival (OS) of a programmatic change in surgical approach to advanced epithelial ovarian cancer...
The incidence of isolated paraaortic nodal metastasis in surgically staged endometrial cancer patients with negative pelvic lymph nodesNadeem R Abu-Rustum
Memorial Sloan Kettering Cancer Centerm, 1275 York Ave, NY, NY 10065, USA
Gynecol Oncol 115:236-8. 2009..To describe the incidence of isolated paraaortic nodal metastasis in surgically staged endometrial cancer patients with negative pelvic lymph nodes...
A prospective outcomes analysis of palliative procedures performed for malignant intestinal obstruction due to recurrent ovarian cancerDennis S Chi
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Oncologist 14:835-9. 2009..To obtain prospective outcomes data on patients (pts) undergoing palliative operative or endoscopic procedures for malignant bowel obstruction due to recurrent ovarian cancer...
Postoperative intra-abdominal collections using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier at the time of laparotomy for ovarian, fallopian tube, or primary peritoneal cancersMario M Leitao
Division of Gynecology, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
Gynecol Oncol 115:204-8. 2009..To determine whether HA-CMC was associated with the development of postoperative intra-abdominal collections in patients undergoing laparotomy for ovarian, fallopian tube, or primary peritoneal malignancies...
Radical abdominal trachelectomy for stage IB1 cervical cancer at 15-week gestationNadeem R Abu-Rustum
Department of Surgery, Gynecology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
Gynecol Oncol 116:151-2. 2010..Radical trachelectomy may broaden the treatment options for pregnant women with stage IB1 cervical cancer who have a strong desire to avoid definitive pregnancy termination and commence treatment without delay...
A nomogram for predicting overall survival of women with endometrial cancer following primary therapy: toward improving individualized cancer careN R Abu-Rustum
Department of Surgery, Gynecology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Gynecol Oncol 116:399-403. 2010..Our objective was to develop a clinically useful nomogram in the hope of providing a more individualized and accurate estimation of overall survival (OS) following primary therapy...
Endometrial sampling diagnosis of FIGO grade 1 endometrial adenocarcinoma with a background of complex atypical hyperplasia and final hysterectomy pathologyMario M Leitao
Division of Gynecology, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Am J Obstet Gynecol 202:278.e1-6. 2010....
A pilot study using the Gynecologic Cancer Lymphedema Questionnaire (GCLQ) as a clinical care tool to identify lower extremity lymphedema in gynecologic cancer survivorsJeanne Carter
Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Gynecol Oncol 117:317-23. 2010..This study aimed to determine the feasibility and efficacy of using the Gynecologic Cancer Lymphedema Questionnaire (GCLQ) as a symptom scale for lymphedema of the lower extremity (LLE)...
An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT)Dennis S Chi
Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Gynecol Oncol 124:10-4. 2012..We analyzed the outcomes of patients treated with PDS at our institution during the same time period in which the EORTC-NCIC trial was conducted, using identical inclusion criteria...
Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: a prospective study using office endometrial biopsyR R Barakat
Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 18:3459-63. 2000..To determine the frequency of developing abnormal pathologic changes in the endometria of tamoxifen-treated women. To characterize the type of pathologic changes involved...
Optimal therapy and management of endometrial cancerYukio Sonoda
Department of Surgery, Memorial Sloan Kettering Cancer Center, Gynecology Service Academic Office, New York, NY 10021, USA
Expert Rev Anticancer Ther 3:37-47. 2003..Controversy in management exists as to the approach and extent of primary surgery as well as the indications for adjuvant therapy. Management of this disease is reviewed...
Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-upRichard R Barakat
Gynecology Service, Department of Surgery, Gynecology Disease Management Team, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 20:694-8. 2002..To determine long-term survival and predictors of recurrence in a retrospective cohort of patients with epithelial ovarian cancer treated with intraperitoneal (IP) chemotherapy...
Cervical neoplasia and the HIV-infected patientElizabeth Stier
General Gynecology Section, Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Hematol Oncol Clin North Am 17:873-87. 2003..Hopefully, as patients live longer and healthier on HAART, they will be more compliant with cervical cancer screening, and cervical cancer will become an increasingly rare disease...
Laparoscopy 2003: oncologic perspectiveNadeem R Abu-Rustum
Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Clin Obstet Gynecol 46:61-9. 2003
Total laparoscopic radical hysterectomy with pelvic lymphadenectomy using the argon-beam coagulator: pilot data and comparison to laparotomyNadeem R Abu-Rustum
Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, NewYork, NY 10021, USA
Gynecol Oncol 91:402-9. 2003..The aim of this study was to describe the feasibility and outcome of total laparoscopic radical hysterectomy with pelvic lymphadenectomy for stage I cervical cancer using the argon-beam coagulator...
Management of early ovarian cancerYukio Sonoda
Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Oncology (Williston Park) 18:343-56; discussion 358, 361-2. 2004..Ideally, these patients should have access to a gynecologic oncologist prior to their initial surgical procedure...
Recurrent cervical cancerMario M Leitao
Memorial Sloan Kettering Cancer Center, Gynecology Service, Department of Surgery, c o Gynecology Service Academic Office, 1275 York Avenue, Room MRI 1027, New York, NY 10021, USA
Curr Treat Options Oncol 3:105-11. 2002..Patients whose recurrences extend close to the pelvic sidewalls should be referred to centers where HDR-IORT is available...
Transperitoneal laparoscopic pelvic and para-aortic lymph node dissection using the argon-beam coagulator and monopolar instruments: an 8-year study and description of techniqueNadeem R Abu-Rustum
Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Gynecol Oncol 89:504-13. 2003....
A fertility-sparing alternative to radical hysterectomy: how many patients may be eligible?Yukio Sonoda
Department of Surgery, Gynecology Service Acadenic Office, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Gynecol Oncol 95:534-8. 2004..To determine the percentage of patients with early-stage cervical cancer who may be eligible for fertility preservation with laparoscopic radical vaginal trachelectomy (LRVT)...
Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterusMario M Leitao
Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Gynecol Oncol 91:209-12. 2003..The purpose of this study was to determine the incidence of lymph node and ovarian metastases in newly diagnosed uterine leiomyosarcoma (LMS), and to describe possible predictive factors...
The benefit of video-assisted thoracoscopic surgery before planned abdominal exploration in patients with suspected advanced ovarian cancer and moderate to large pleural effusionsDennis S Chi
Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Gynecol Oncol 94:307-11. 2004..To analyze the findings and impact on the management of video-assisted thoracoscopic surgery (VATS) before planned abdominal exploration in patients with suspected advanced ovarian cancer and moderate to large pleural effusions...
Gynecologic cancer treatment and the impact of cancer-related infertilityJeanne Carter
Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Gynecol Oncol 97:90-5. 2005..The objective of this study was to empirically assess the emotional and sexual impact of cancer-related infertility in women with a history of gynecologic cancer...
Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approachDennis S Chi
Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Gynecol Oncol 94:650-4. 2004....
The safety and efficacy of laparoscopic surgical staging of apparent stage I ovarian and fallopian tube cancersDennis S Chi
Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Am J Obstet Gynecol 192:1614-9. 2005..To compare the safety and efficacy of laparoscopic staging of ovarian or fallopian tube cancers to staging via laparotomy for epithelial ovarian carcinoma...
Temozolomide in uterine leiomyosarcomasSibyl Anderson
Developmental Chemotherapy, Gynecology Disease Management Team, Memorial Sloan Kettering Cancer Center, Gynecology Breast Services Academic Office, 1275 York Avenue, MRI 1027, New York, NY 10021, USA
Gynecol Oncol 98:99-103. 2005..We include a literature review of temozolomide activity in leiomyosarcoma patients...
Subcutaneous tumor implantation after laparoscopic procedures in women with malignant diseaseNadeem R Abu-Rustum
Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, MRI 1026, New York, NY 10021, USA
Obstet Gynecol 103:480-7. 2004..To describe the incidence of clinically detected laparoscopy-related subcutaneous tumor implantation in women with malignant disease who were treated by a gynecologic oncology service...
Follow-up study of the correlation between postoperative computed tomographic scan and primary surgeon assessment in patients with advanced ovarian, tubal, or peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual diseaDennis S Chi
Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, MRI 1026, 1275 York Ave, New York, NY 10021, USA
Int J Gynecol Cancer 20:353-7. 2010..This is a follow-up analysis of survival and prognostic factors for patients who had concordant and discordant postoperative CT scan findings...
The effects of CO2 pneumoperitoneum on the survival of women with persistent metastatic ovarian cancerNadeem R Abu-Rustum
Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Gynecol Oncol 90:431-4. 2003....
Radical trachelectomy via a trans-sacral approach: a case reportYukio Sonoda
Department of Gynecologic Oncology, Centre Oscar Lambret, Lille, France
Gynecol Oncol 90:466-70. 2003..Endometrial cancer may arise in patients previously treated for rectal cancer. Surgical management can be challenging, and the gynecologic oncologist may need to employ alternative surgical approaches...
Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trialMartee L Hensley
Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 20:2824-31. 2002..The median time to progression was 5.6 months (range, 4 to 10 months). CONCLUSION: Gemcitabine plus docetaxel is tolerable and highly active in treated and untreated patients with LMS...
A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcomaVicky Makker
Memorial Sloan Kettering Cancer Center Department of Medicine, Gynecologic Medical Oncology Service, New York, NY, USA
Gynecol Oncol 111:249-54. 2008..To determine the progression-free survival (PFS) and overall survival (OS) in a cohort of patients who received either platinum-based chemotherapy with or without radiation therapy (pelvic or WAI), or RT alone...
The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatmentRoisin O'Cearbhaill
Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Gynecol Oncol 116:326-31. 2010....
Treatment of advanced uterine leiomyosarcoma with aromatase inhibitorsRoisin O'Cearbhaill
Department of Medicine, Gynecology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Gynecol Oncol 116:424-9. 2010..Aromatase inhibitors are sometimes used in the treatment of selected patients with uterine leiomyosarcoma (LMS), but there are few data assessing the efficacy of aromatase inhibitors in this setting...
Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective studyMika A Sovak
Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Gynecol Oncol 103:451-7. 2006..CONCLUSION: TC is a well tolerated, active regimen in the treatment of resected, high-risk stage III and IV endometrial cancer that warrants further investigation...
Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancerCatherine S M Diefenbach
Gynecologic Medical Oncology, Department of Medicine, Howard 903, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Gynecol Oncol 104:435-42. 2007..In this study, we examined the frequency of serum elevation as well as the diagnostic and prognostic significance of this serum marker in endometrial cancer...
Complex atypical hyperplasia of the uterus: characteristics and prediction of underlying carcinoma riskMario M Leitao
Division of Gynecology, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Am J Obstet Gynecol 203:349.e1-6. 2010..The objective of the study was to identify additional factors that may improve the ability to predict underlying carcinoma risk in patients with complex atypical hyperplasia (CAH) of the uterus...
Ventral hernia following primary laparotomy for ovarian, fallopian tube, and primary peritoneal cancersKara C Long
Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Gynecol Oncol 120:33-7. 2011..To evaluate the incidence and risk factors for ventral hernia development following primary laparotomy for ovarian, fallopian tube, and peritoneal cancers...
Pre- and postmenopausal high-risk women undergoing screening for ovarian cancer: anxiety, risk perceptions, and quality of lifeMartee L Hensley
Department of Medicine, Memorial Sloan Kettering Cancer Center, 1278 York Avenue, New York, NY 10021 6094, USA
Gynecol Oncol 89:440-6. 2003..We sought to determine whether anxiety, depression, perception of ovarian cancer risk, and false-positive test frequency differed between high-risk premenopausal and postmenopausal women initiating ovarian cancer screening...
Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remissionCatherine S M Diefenbach
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 14:2740-8. 2008..In this study, we describe the effects of vaccination with the HLA-A*0201-restricted NY-ESO-1b peptide on patients with epithelial ovarian cancer in high-risk first remission...
A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancerJason Konner
Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Gynecol Oncol 110:140-5. 2008..Determine the safety and efficacy of cetuximab plus paclitaxel and carboplatin as initial treatment of stage III/IV ovarian cancer...
Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I studyJason A Konner
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Clin Cancer Res 16:5288-95. 2010..This phase I, dose-escalation study was conducted to determine the safety of weekly i.v. farletuzumab and establish the maximum tolerated dose (MTD)...
What is the incidence of isolated paraaortic nodal recurrence in grade 1 endometrial carcinoma?Nadeem R Abu-Rustum
Department of Surgery, Gynecology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Gynecol Oncol 111:46-8. 2008..To describe the incidence of isolated paraaortic nodal recurrences in patients with a final diagnosis of grade 1 endometrial carcinoma initially treated with surgery...
Gemcitabine-induced peripheral edema: report on 15 cases and review of the literatureChristopher G Azzoli
Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Am J Clin Oncol 26:247-51. 2003..Patients predisposed to peripheral edema from some other cause may be at increased risk for developing severe peripheral edema with gemcitabine...
Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II studyMartee L Hensley
Memorial Sloan Kettering Cancer Center, Department of Medical Oncology, 1275 York Avenue, New York, NY 10065, USA
Gynecol Oncol 115:460-5. 2009..We also aimed to characterize the toxicity of sunitinib and to estimate time-to-progression...
A phase I trial of pemetrexed plus gemcitabine given biweekly with B-vitamin support in solid tumor malignancies or advanced epithelial ovarian cancerMartee L Hensley
Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
Clin Cancer Res 14:6310-6. 2008..To determine the maximally tolerated dose (MTD) of biweekly pemetrexed with gemcitabine plus B(12) and folate supplementation in patients with advanced solid tumors and ovarian cancer...
Cognitive functions in long-term survivors of ovarian cancerDenise D Correa
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Gynecol Oncol 119:366-9. 2010..This cross-sectional study assessed neuropsychological functions in long-term survivors of ovarian cancer who were either in complete remission or with evidence of recurrent disease...
Costs of treatment and outcomes associated with second-line therapy and greater for relapsed ovarian cancerMonica Prasad
Developmental Chemotherapy Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Gynecol Oncol 93:223-8. 2004..Topotecan was more costly to deliver. Although a larger percentage of patients received clinical benefit with topotecan use, this likely reflects physician selection for use of topotecan earlier in the course of disease...
Phase II study of sorafenib in patients with metastatic or recurrent sarcomasRobert G Maki
Melanoma Sarcoma Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Howard 909, New York, NY 10065, USA
J Clin Oncol 27:3133-40. 2009..Further evaluation of sorafenib in these and possibly other sarcoma subtypes appears warranted, presumably in combination with cytotoxic or kinase-specific agents...
Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II studyMartee L Hensley
Memorial Sloan Kettering Cancer Center, Department of Medical Oncology, 1275 York Avenue, New York, NY 10021, USA
Gynecol Oncol 109:323-8. 2008..There is no standard second-line therapy. We determined activity of fixed-dose rate gemcitabine plus docetaxel as second-line treatment for metastatic uterine leiomyosarcoma...
Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancerPaul J Sabbatini
Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 13:4170-7. 2007....
A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignanciesCarol Aghajanian
The Developmental Chemotherapy Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 8:2505-11. 2002..v. bolus for 2 weeks, followed by a 1-week recovery period in patients with advanced solid tumor malignancies...
Early detection and prognosis of ovarian cancer using serum YKL-40Jakob Dupont
Developmental Chemotherapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Howard 905, 1275 York Ave, New York, NY 10021, USA
J Clin Oncol 22:3330-9. 2004..YKL-40 is a secreted glycoprotein (chitinase family). We compared YKL-40 with two ovarian cancer serum markers, CA125 and CA15-3, for the detection of early-stage ovarian cancer...
Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomasCarol Aghajanian
Developmental Chemotherapy Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 25:1082-8. 2007..Dosing schedules of 40 mg/m2 and 50 mg/m2 over 3 hours were also evaluated...
Epithelial ovarian cancerMartee L Hensley
Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Curr Treat Options Oncol 3:131-41. 2002..Novel approaches to managing minimal residual disease are being tested in hopes of decreasing the number of patients who relapse after achieving complete clinical remission...
Economic outcomes of breast cancer survivorship: CALGB study 79804Martee L Hensley
Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Breast Cancer Res Treat 91:153-61. 2005..Over 80% of women diagnosed with breast cancer will be survivors. We sought to determine the economic consequences of surviving breast cancer...
Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergyDon S Dizon
Developmental Chemotherapy Service, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Gynecol Oncol 84:378-82. 2002..Routine retreatment of carboplatin-allergic patients with cisplatin in the relapsed setting cannot be recommended without careful consideration of potential risks and benefits...
Ovarian carcinoma screening in women at intermediate risk: impact on quality of life and need for invasive follow-upNoah D Kauff
Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Cancer 104:314-20. 2005..Limited information is available regarding the impact of this approach on either quality of life (QOL) or need for invasive follow-up in this group of women...
Transfusion utilization during adnexal or peritoneal cancer surgery: effects on symptomatic venous thromboembolism and survivalNadeem R Abu-Rustum
Department of Surgery, Gynecology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Room C 1096, New York, NY 10021, USA
Gynecol Oncol 99:320-6. 2005....
Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]Robert G Maki
Department of Medicine, Memorial Sloan Kettering Cancer Center New York, NY 10021, USA
J Clin Oncol 25:2755-63. 2007..To determine if the addition of docetaxel to gemcitabine improved clinical outcome of patients with metastatic soft tissue sarcomas, we compared a fixed dose rate infusion of gemcitabine versus a lower dose of gemcitabine with docetaxel...
